A Scenario-Based Mathematical Modeling of HIV Control in Nigeria Integrating Superinfection, Drug Resistance, and Future Vaccine Introduction
DOI:
https://doi.org/10.62054/ijdm/0203.11Abstract
This study develops a mathematical model of HIV transmission in Nigeria to assess how scaling up antiretroviral therapy, promoting behavioral change, and managing drug resistance could shape epidemic outcomes, while also exploring the potential added impact of introducing a future HIV vaccine. The model incorporates eight interconnected compartments representing susceptible, infected with primary and secondary infections, treated individuals, drug-resistant cases, vaccinated, recovered with partial immunity, and behavioral intervention. Parameterized with epidemiological data for Nigeria, the model explores Nigerian epidemic pattern under distinct and combined control measures. Simulation results show that early and high-coverage vaccination, specifically with high-efficacy and slow waning, reduces both primary and secondary infections. ART coverage is observed to be critical in curbing the resistant strain, while behavioral reinforcement amplifies the effectiveness of biomedical interventions. However, scenarios with poor ART adherence or high superinfection potential reveal resurgence in resistant infections, emphasizing the danger posed by superinfection. Combined strategy simulations produced the most significant and sustained reductions in HIV prevalence and resistance burden. The findings in this study underscore the importance of coordinated, multi-pronged strategies for HIV control in Nigeria. The model offers a valuable policy tool for evaluating trade-offs between intervention options and guiding data-driven public health planning.
References
Bartsch, S. M., Nilles, E. J., & Lee, B. Y. (2020). The potential health and economic value of a hypothetical HIV vaccine in the United States. Vaccine, 38(20), 3621–3628. https://doi.org/10.1016/j.vaccine.2020.03.046
Garske, T., Ferguson, N. M., & Cori, A. (2022). Modeling the impact of vaccination on HIV transmission in Africa: A scenario-based approach. Epidemics, 38, 100526. https://doi.org/10.1016/j.epidem.2021.100526
Chakraborty, S., Bhunu, C. P., & Mushayabasa, S. (2023). Modeling the effect of HIV vaccine implementation under ART and behavior change. Journal of Theoretical Biology, 560, 111393. https://doi.org/10.1016/j.jtbi.2023.111393
Silal, S. P., Mhlanga, M., & Pulliam, J. R. C. (2024). Forecasting the role of an HIV vaccine in sub-Saharan Africa using scenario-based modeling. BMC Infectious Diseases, 24(1), 134. https://doi.org/10.1186/s12879-024-08712-w
WHO. (2023a) HIV/AIDS. https://www.who.int/news-room/fact-sheets/detail/hiv-aids
WHO. (2025a). Data on the size of the HIV epidemic: Situation & trends. WHO Global Health Observatory. https://www.who.int/data/gho/data
/themes/hiv aids/data on the size of the hiv aids epidemic
Onyedika Ugoeze, N., & Adegoke, J. (2025, June 20). Africa accounts for about 25.9 million (65 per cent) of global HIV burden; Nigeria contributes about 1.9 million. The Guardian. https://www.guardian.ng/news/africa accounts for 65 of global hiv burden/
NIH HIVinfo. (2024, July 26). What is a preventive HIV vaccine? U.S. National Institutes of Health. https://hivinfo.nih.gov/understanding-hiv/fact sheets/what-preventive-hiv-vaccine
HIV.gov. (2024, August 30). HIV vaccines: Potential future options. U.S. Department of Health and Human Services. https://www.hiv.gov/hiv-basics/hiv-prevention/potential-future-options/hiv-vaccines
IAVI & Scripps Research. (2025, May 15). Two HIV vaccine trials show proof of concept for pathway to broadly neutralizing antibodies. IAVI / Scripps Research. https://iavi.org
/press-release/two-hiv-vaccine-trials-show-proof-of-concept-for-pathway-to-broadly-neutralizing-antibodies
National Institute of Allergy and Infectious Diseases (NIAID). (2023, December 14). NIH research identifies opportunities to improve future HIV vaccine candidates. U.S. Department of Health and Human Services. https://www.nih.gov/news-events/news-releases/nih-research-identifies-opportunities-improve-future-hiv-vaccine-candidates
Boomgarden, A. C., & Upadhyay, C. (2025). Progress and challenges in HIV 1 vaccine research: A comprehensive overview. Vaccines, 13(2), 148. https://doi.org/10.3390
/vaccines13020148
Govindan, R., & Stephenson, K. E. (2024). HIV vaccine development at a crossroads: New B and T cell approaches. Vaccines (Basel), 12(9), 1043. https://doi.org/10.3390
/vaccines12091043
Scott, G. Y., & Worku, D. (2024). HIV vaccination: Navigating the path to a transformative breakthrough—A review of current evidence. Health Science Reports, 7(9), e70089. https://doi.org/10.1002/hsr2.70089
Shim, I., Rogowski, L., & Venketaraman, V. (2025). Progress and recent developments in HIV vaccine research. Vaccines, 13(7), 690. https://doi.org/10.3390/vaccines13070690
Hendrix, A., Sperling, R., Gelber, R., Kiselev, P., & Scott, G. (2023). Impact of universal testing and treatment (HPTN 071 PopART) on HIV incidence: A model-based assessment of treatment-as-prevention in southern Africa. New England Journal of Medicine.
Anderson, R. M., & Garnett, G. P. (2000). Mathematical models of the transmission and control of sexually transmitted diseases. Sexually Transmitted Diseases, 27(10), 636–643. https://doi.org/10.1097/00007435-200011000-00010
Dimitrov, D. T., Selinger, C., Welkhoff, P. A., & Bershteyn, A. (2021). Modeling the future of a partially effective HIV vaccine: assessing limitations at the population level. PLoS Medicine, 17(6), e1003401. https://doi.org/10.1371/journal.pmed.1003401
Gilbert, P. B., Huang, Y., & Janes, H. E. (2016). Modeling HIV vaccine trials of the future. Current Opinion in HIV and AIDS, 11(6), 620–627. https://doi.org/10.1097/COH.0000000000000314
UNAIDS. (2024). Nigeria: Country factsheets. Retrieved from https://www.unaids.org/en/regionscountries/countries/nigeria
Maduakolam, I. O., Ogbonnaya, N. P., Ndubuisi, I. F., Ekechukwu, N. D., & Okoronkwo, I. L. (2022). Effects of structured health education on prevention of HIV risky behaviours among adolescents in Nigeria: A pragmatic randomized controlled trial. Libyan Journal of Medicine, 17(1), 2128414. https://doi.org/10.1080/19932820.2022.2128414
Loosli, T., Hauser, A., Josi, J., Ingle, S. M., Sighem, A. v., Gill, M. J., … & Lessells, R. (2024). Predicting emergent dolutegravir resistance in South Africa: A modelling study. medRxiv. https://doi.org/10.1101/2024.07.20.24310740
AIDS Research and Therapy. (2025). Global HIV epidemiology and burden of primary infection. AIDS Res Ther, 22(1), 14.
CDC). (2025). HIV Surveillance Report, 2025. U.S. Department of Health and Human Services. https://www.cdc.gov/hiv/library
/reports/hiv-surveillance.html
Macrotrends. (2025). Nigeria Population 1950-2025. https://www.macrotrends.net/countries
/NGA/nigeria/population
UNAIDS. (2025). HIV estimates with uncertainty bounds 1990–2025. Joint United Nations Programme on HIV/AIDS. https://www.unaids.org/en/resources/documents
WHO. (2025b). Global Health Observatory: HIV/AIDS. World Health Organization. https://www.who.int/data/gho/data/themes/hiv-aids
World Bank. (2025). World Development Indicators: Nigeria birth and death rates. https://data.worldbank.org/indicator/SP.DYN.CBRT.IN
Worldometer. (2025). Nigeria Population Live Data. https://www.worldometers.info/world-population/nigeria-population/
Smith, R. J., & Koelle, K. (2024). Modeling HIV superinfection and the impact of strain diversity on epidemic control. Journal of Theoretical Biology, 575, 111234. https://doi.org/10.1016/j.jtbi.2023.111234
WHO. (2023b). HIV Drug Resistance Report 2023. WHO. https://www.who.int/publications/i/item/9789240060443
Douek, D. C., Roederer, M., & Koup, R. A. (2009). Emerging concepts in the immunopathogenesis of AIDS. Annual Review of Medicine, 60, 471–484. https://doi.org/10.1146/annurev.med.60.041807.123549
Bekker, L. G., Hosek, S., & Pettifor, A. (2022). Behavioral interventions to reduce HIV risk: Reaching key populations globally. Current HIV/AIDS Reports, 19(1), 12–23. https://doi.org/10.1007/s11904-021-00570-4
Granich, R. M., Gilks, C. F., Dye, C., De Cock, K. M., & Williams, B. G. (2009). Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model. The Lancet, 373(9657), 48–57. https://doi.org/10.1016/S0140-6736(08)61697-9
Koelle, K., & Rasmussen, D. A. (2021). Superinfection in HIV: Epidemiological and evolutionary implications. Current Opinion in HIV and AIDS, 16(2), 93–100. https://doi.org/10.1097/COH.0000000000000672
Castro, H., Pillay, D., & Sabin, C. A. (2017). Transmission of HIV-1 drug resistance and the implications for treatment and prevention strategies. Journal of Infectious Diseases, 216(suppl_9), S802–S807. https://doi.org/10.1093/infdis/jix418
Conway, J. M., & Perelson, A. S. (2018). Modeling the immune response to HIV infection. Current Opinion in Systems Biology, 11, 25–31. https://doi.org/10.1016/j.coisb
.2018.06.002
Nowak, M. A., May, R. M., & Anderson, R. M. (1990). The evolutionary dynamics of HIV superinfection. Nature, 348(6301), 261–262. https://doi.org/10.1038/348261a0
Eaton, J. W., Johnson, L. F., Salomon, J. A., Bärnighausen, T., Bendavid, E., Bershteyn, A., Bloom, D. E., Cambiano, V., Fraser, C., Hontelez, J. A. C., Humair, S., Klein, D. J., Long, E. F., Phillips, A. N., Pretorius, C., Stover, J., Wenger, E. A., Williams, B. G. & Hallett, T. B. (2012). HIV treatment as prevention: Systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Medicine, 9(7): e1001245. https://doi.org/10.1371/journal
.pmed.1001245
Rhodes, T., & Simic, M. (2020). Efficacy of behavioral interventions in HIV prevention: Systematic review and meta-analysis. AIDS Reviews, 22(3), 143–153. https://doi.org
/10.24875/AIDSRev.20000131
UNAIDS. (2024). Global HIV & AIDS statistics – 2024 fact sheet. https://www.unaids
.org/en/resources/fact-sheet
Mendicino, C. C. P., Silva, G. J. D., Braga, L. P., Colosimo, E. A., & Guimarães, M. D. C. (2021). Immune recovery after antiretroviral therapy initiation: A challenge for people living with HIV in Brazil. Cadernos de Saúde Pública, 37(9), Article e00143520. https://doi.org/10.1590/0102 311X00143520 onlinelibrary.wiley.com+5
CDC. (2023). Vital statistics rapid release: Mortality in the U.S., 2023. CDC. https://www.cdc.gov/nchs/products/vsr.htm
Whiley, R. A., Nargis P., Mushtaq, N., Hagi-Pavli, E., Personne, Y., Javaid, D. & Waite, R. D. (2014). Differential Potentiation of the Virulence of the Pseudomonas aeruginosa Cystic Fibrosis Liverpool Epidemic Strain by Oral Commensal Streptococci, The Journal of Infectious Diseases, 209(5), 769–780, https://doi.org/10.1093/infdis/jit568
Feder, A. F., (2021). Understanding evolution of drug resistance in HIV at population and within-host levels. eLife, 10, e69032. https://doi.org/10.7554/eLife.69032
Mavedzenge, S. N., Luecke, E., & Ross, D. A. (2019). Effective HIV prevention strategies: The role of behavioral campaigns. PLOS ONE, 14(6), e0218745. https://doi.org
/10.1371/journal.pone.0218745
Gillman, A. S., Iles, I. A., Klein, W. M., Biesecker, B. B., Lewis, K. L., Biesecker, L. G. & Ferrer, R. A. (2022). The role of future-oriented affect in engagement with genomic testing results. J Behav Med 45, 103–114 (2022). https://doi.org/10.1007/s10865-021-00253-7
Omale, D., Ojih, P. B., Atokolo, W., Omale, A. J., & Bolaji, B. (2021). Mathematical model for transmission dynamics of HIV and tuberculosis co-infection in Kogi State, Nigeria. Journal of Mathematical and Computational Science, 11(5), 5580-5613, https://doi.org/10.28919/jmcs/6080
Rasheed, A., Raza, A., & Omame, A. (2025). Analysis of a novel mathematical model for HBV and HIV incorporating vertical transmission and intervention measures. Modeling Earth Systems and Environment, 3, https://doi.org/10.1007/s40808-025-02408-w
Eguavoen, A., Larson, H. J., Chinye-Nwoko, F., & Ojeniyi, T. (2023). Reducing COVID-19 vaccine hesitancy and improving vaccine uptake in Nigeria. Journal of public health in Africa, 14(5), 2290. https://doi.org/10.4081/jphia.2023.2290
Downloads
Published
Data Availability Statement
The values of all parameters and state variables used in this work were provided in Tables 1 and 2, with their verifiable sources referenced accordingly.
Issue
Section
License
Copyright (c) 2025 International Journal of Development Mathematics (IJDM)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are solely responsible for obtaining permission to reproduce any copyrighted material contained in the manuscript as submitted. Any instance of possible prior publication in any form must be disclosed at the time the manuscript is submitted and a
copy or link to the publication must be provided.
The Journal articles are open access and are distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs 4.0 IGO License, which permits use,
distribution, and reproduction in any medium, provided the original work is properly cited.
No modifications or commercial use of the articles are permitted.
